CTI BioPharma (CTIC) Misses Q1 EPS by 1c

CTI BioPharma (NASDAQ: CTIC) reported Q1 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22).

"The U.S. Food and Drug Administration's (FDA) acceptance of our New Drug Application (NDA) for pacritinib with priority review and a Prescription Drug User Fee Act (PDUFA) action date of November 30, 2021 brings us one step closer to providing pacritinib to myelofibrosis patients with severe thrombocytopenia who are underserved by existing therapies," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We continue to work diligently on our commercial preparedness and expect to be ready to launch pacritinib in the United States this year, pending approval by the FDA. To that end, over the last quarter, we progressed key pre-commercial activities to prepare for a successful and rapid launch upon approval, including market access, distribution and supply chain, disease education and field force planning and deployment. We look forward to continuing these efforts, and to work closely with the FDA during its review of our application."

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c